What happened
A precision medicine trial of bupropion and sertraline for major depressive disorder using a biomarker-guided sequential multiple-assignment design
SourceNature Mental HealthpublicationBiotech
A precision medicine trial of bupropion and sertraline for major depressive disorder using a biomarker-guided sequential multiple-assignment design
Publication signal: A precision medicine trial of bupropion and sertraline for major depressive disorder using a biomarker-guided sequential multiple-assignment design
Factual summary
Why it matters
Recent source-backed research output for AISci Stage A browsing.
SourceNature Mental HealthLimitations
AISci rank score does not assess scientific quality or citation impact.
SourceNature Mental HealthLinked output
A precision medicine trial of bupropion and sertraline for major depressive disorder using a biomarker-guided sequential multiple-assignment designpaperPeople
No reviewed person relationship is attached to this event.
Organizations
No reviewed organization relationship is attached to this event.
Topics
Problems
No reviewed problem relationship is attached to this event.
Relationship evidence
Diagnostics and Biomarkers
Controlled AISci Stage A topic for Diagnostics and Biomarkers.
A precision medicine trial of bupropion and sertraline for major depressive disorder using a biomarker-guided sequential multiple-assignment design
A precision medicine trial of bupropion and sertraline for major depressive disorder using a biomarker-guided sequential multiple-assignment design
Timeline
- publicationA precision medicine trial of bupropion and sertraline for major depressive disorder using a biomarker-guided sequential multiple-assignment design